Marker Therapeutics Stock Probability of Future Stock Price Finishing Over 3.26

MRKR Stock  USD 3.26  0.07  2.10%   
Marker Therapeutics' future price is the expected price of Marker Therapeutics instrument. It is based on its current growth rate as well as the projected cash flow expected by the investors. This tool provides a mechanism to make assumptions about the upside potential and downside risk of Marker Therapeutics performance during a given time horizon utilizing its historical volatility. Check out Marker Therapeutics Backtesting, Marker Therapeutics Valuation, Marker Therapeutics Correlation, Marker Therapeutics Hype Analysis, Marker Therapeutics Volatility, Marker Therapeutics History as well as Marker Therapeutics Performance.
To learn how to invest in Marker Stock, please use our How to Invest in Marker Therapeutics guide.
  
At this time, Marker Therapeutics' Price Book Value Ratio is relatively stable compared to the past year. As of 11/27/2024, Price Earnings To Growth Ratio is likely to grow to 0.08, while Price Earnings Ratio is likely to drop (3.62). Please specify Marker Therapeutics' target price for which you would like Marker Therapeutics odds to be computed.

Marker Therapeutics Target Price Odds to finish over 3.26

The tendency of Marker Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to move above the current price in 90 days
 3.26 90 days 3.26 
about 50.73
Based on a normal probability distribution, the odds of Marker Therapeutics to move above the current price in 90 days from now is about 50.73 (This Marker Therapeutics probability density function shows the probability of Marker Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days the stock has the beta coefficient of 2.49 . This indicates as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Marker Therapeutics will likely underperform. Additionally Marker Therapeutics has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial.
   Marker Therapeutics Price Density   
       Price  

Predictive Modules for Marker Therapeutics

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Marker Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Hype
Prediction
LowEstimatedHigh
0.163.2610.59
Details
Intrinsic
Valuation
LowRealHigh
0.142.8510.18
Details
Naive
Forecast
LowNextHigh
0.073.5210.85
Details
1 Analysts
Consensus
LowTargetHigh
36.4040.0044.40
Details

Marker Therapeutics Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. Marker Therapeutics is not an exception. The market had few large corrections towards the Marker Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Marker Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Marker Therapeutics within the framework of very fundamental risk indicators.
α
Alpha over Dow Jones
-0.25
β
Beta against Dow Jones2.49
σ
Overall volatility
0.55
Ir
Information ratio -0.01

Marker Therapeutics Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Marker Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Marker Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
Marker Therapeutics had very high historical volatility over the last 90 days
Marker Therapeutics has a very high chance of going through financial distress in the upcoming years
The company reported the previous year's revenue of 3.31 M. Net Loss for the year was (14.05 M) with loss before overhead, payroll, taxes, and interest of (17.13 M).
Marker Therapeutics currently holds about 18.08 M in cash with (16.44 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.22.
Roughly 12.0% of the company outstanding shares are owned by corporate insiders
Latest headline from news.google.com: Marker Therapeutics gets 2M NIH grant for MT-601 Phase 1 study - MSN

Marker Therapeutics Price Density Drivers

Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Marker Stock often depends not only on the future outlook of the current and potential Marker Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Marker Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding8.8 M
Cash And Short Term Investments15.1 M

Marker Therapeutics Technical Analysis

Marker Therapeutics' future price can be derived by breaking down and analyzing its technical indicators over time. Marker Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Marker Therapeutics. In general, you should focus on analyzing Marker Stock price patterns and their correlations with different microeconomic environments and drivers.

Marker Therapeutics Predictive Forecast Models

Marker Therapeutics' time-series forecasting models is one of many Marker Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Marker Therapeutics' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

Things to note about Marker Therapeutics

Checking the ongoing alerts about Marker Therapeutics for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Marker Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Marker Therapeutics had very high historical volatility over the last 90 days
Marker Therapeutics has a very high chance of going through financial distress in the upcoming years
The company reported the previous year's revenue of 3.31 M. Net Loss for the year was (14.05 M) with loss before overhead, payroll, taxes, and interest of (17.13 M).
Marker Therapeutics currently holds about 18.08 M in cash with (16.44 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.22.
Roughly 12.0% of the company outstanding shares are owned by corporate insiders
Latest headline from news.google.com: Marker Therapeutics gets 2M NIH grant for MT-601 Phase 1 study - MSN

Additional Tools for Marker Stock Analysis

When running Marker Therapeutics' price analysis, check to measure Marker Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Marker Therapeutics is operating at the current time. Most of Marker Therapeutics' value examination focuses on studying past and present price action to predict the probability of Marker Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Marker Therapeutics' price. Additionally, you may evaluate how the addition of Marker Therapeutics to your portfolios can decrease your overall portfolio volatility.